|Last Name: ||Mulshine|
|First Name: ||James|
|M. I.: ||L. |
|Degree & Certifications: ||MD|
|Endowed Professorship: |
|Rank & Title: ||Professor|
Dean, Graduate College (Acting)
|Department: ||Internal Medicine|
|College: ||Graduate College, Rush Medical College, Rush University|
|Office Location: ||Armour Academic Center|
600 S. Paulina St.
Chicago, IL 60612-3823
|Laboratory Location: |
|Phone: ||(312) 942-3589|
|Fax: ||(312) 942-8331|
|Education: ||MD, Loyola Stritch School of Medicine, 1977|
BA, College of the Holy Cross, 1974
|Research Areas: ||Biological Phenomena Cell Phenomena and Immunity, Neoplasms|
|Laboratory Techniques: ||Elisa/Plate reading, Imaging Techonology, Immunohisto-/immunocytochemistry, In Situ Hybridization, PCR, Real-time PCR, si RNA, Western Northern Southern Blotting|
|Faculty/Staff Description: ||
Mulshine's research involves translating basic science into meaningful tools for cancer management, especially for lung cancer management. He has been awarded a number of United States and international patents. His research productivity has been recognized with awards from the Department of Commerce, the Public Health Service, the NIH, and the NCI. He is on numerous editorial and foundation boards involved with lung cancer and prevention research. Mulshine is also a visiting professor at the University of Tokyo Medical University Clinical Proteome Center. Mulshine has worked extensively with academia as well as with industry through collaborative research and development agreements to move cancer management tools into broader clinical application.
In addition to his research activities, Mulshine has had senior administrative responsibilities, such as chairing the NCI's intramural investigational review board and has been the NCI's representative to the NIH's Cooperative Research and development subcommittee. In addition, he co-chairs the upper aerodigestive research faculty in the Center for Cancer Research and is the head of the intervention section in the cell and cancer biology branch of the Center for Cancer Research, NCI. His research has been in developing integrated cancer detection and intervention strategies based on tumor biology. His research has identified particular arachidonic acid metabolites as key factors in promoting upper aerodigestive carcinogenesis. A particular focus is on cancer at a stage of interepithelial neoplasia (IEN), as this is a particularly attractive stage to define safe and effective new treatment strategies. A recently completed randomized, placebo control of a locally delivery cyclooxygenase inhibitor for oral leukoplakia is an example of this approach. He has also extensively published on efforts to develop effective new diagnostic approaches for early epithelial lung cancer and developing complementary tailored approaches to drug delivery to arrest progression or reverse early carcinogenesis. He is currently working on improving the management of spiral CT detected lung cancer in high risk populations.